Our data suggests that additional studies should be performed for the use of specific PI3K p110α inhibitors in CRC patients, particularly those with KRAS mutations who are currently excluded from the biological EGFR-targeted therapies. This evidence concerns the gene PIK3CA and colorectal carcinoma.